The development of efficient immunotherapies requires strong rationalization. We have recently implemented a large analysis of biomarkers in two studies involving the multi-peptide vaccine IMA901 and advanced renal cell cancer patients. Our findings demonstrate that the breadth of immune responses was associated with clinical benefits and that single-dose cyclophosphamide reduced the amount of regulatory T cells and was associated with prolonged survival after vaccination.
Keywords: T cells; biomarkers; cancer; immunomonitoring; immunotherapy; low-dose cyclophosphamide; peptides; randomized clinical trial; regulatory T cells; renal cell cancer; vaccine.